No Data
No Data
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
Vanda Pharmaceuticals Price Target Announced at $11.00/Share by Cantor Fitzgerald
Vanda Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage On Vanda Pharma With Overweight Rating, Announces Price Target of $11
Vanda Pharma Analyst Ratings
Cantor Fitzgerald Initiates Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Announces Target Price $11
Cantor Fitzgerald analyst Charles Duncan initiates coverage on $Vanda Pharmaceuticals(VNDA.US)$ with a buy rating, and sets the target price at $11.According to TipRanks data, the analyst has a
No Data